Gastroenterology and Liver

Non-Alcoholic Fatty Liver Disease (NAFLD) & NASH

NAFLD and NASH have emerged as leading causes of chronic liver disease worldwide, driven by metabolic syndrome, obesity, and lifestyle factors. This session focuses on the pathophysiology, diagnostic approaches, and therapeutic strategies for these conditions. Researchers will present findings on imaging modalities, non-invasive biomarkers, and histopathological evaluations to facilitate early diagnosis and disease staging. The track will highlight lifestyle interventions, pharmacological therapies, and emerging agents targeting fibrosis, inflammation, and metabolic dysregulation, providing attendees with a comprehensive overview of evidence-based management.

In addition, this track will explore precision medicine approaches to NAFLD and NASH, including genetic profiling, risk stratification, and individualized treatment planning. Clinical trials, real-world data, and innovative combination therapies will be discussed to enhance understanding of treatment efficacy and long-term outcomes. Participants will also engage in discussions on public health strategies to mitigate disease burden, including preventive measures, dietary interventions, and patient education. This session aims to foster collaboration, encourage research submissions, and provide actionable insights into one of the most pressing liver health challenges globally.